1 Key Insights

2 SWOT Analysis for Breast Cancer

3 Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Market Overview at a Glance

3.1 Total Market Share (%) Distribution of HR-positive/HER2-negative in 2017
3.2 Total Market Share (%) Distribution of HR-positive/HER2-negative in 2030

4 Disease Background and Overview: Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer

4.1 Introduction
4.2 Types of Breast Cancer
4.2.1 Subtypes of Breast Cancer
4.2.2 Molecular Subtypes of Breast Cancer
4.3 Estrogen Receptor (ER)-Positive Breast Cancer
4.3.1 Estrogen Receptor
4.3.2 Estrogen Receptor 1 Mutations
4.3.3 PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) Gene
4.3.4 GATA 3
4.4 Metabolic Pathway of Estrogen Receptor (ER)-Positive Breast Cancer
4.4.1 Role of Estrogen Receptor Alpha (ER?) in Regulating Breast Cancer Metabolism
4.5 Symptoms of HR-Positive Breast Cancer
4.6 Risk Factors of Estrogen Receptor (ER)-Positive Breast Cancer
4.6.1 Lifestyle-related Breast Cancer Risk Factors
4.6.2 Changes in Other Genes
4.6.3 Having a Family History of Breast Cancer
4.6.4 Having Dense Breast Tissue
4.7 Diagnosis of Estrogen Receptor (ER)-Positive Breast Cancer
4.7.1 Imaging Tests
4.7.2 Biopsy
4.7.3 Genomic Tests to Predict Recurrence Risk
4.7.4 Additional tests
4.8 Diagnostic Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer
4.8.1 American Society of Clinical Oncology (ASCO)

5 Recognized Establishments

6 Epidemiology and Patient Population

6.1 Key Findings
6.2 Population and Forecast Parameters
6.3 Total Incidence of Breast Cancer in the 7MM
6.4 Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM
6.5 Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
6.6 Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM

7 Country-Wise Epidemiology of Hormone Receptor (HR) Positive Breast Cancer

7.1 United States
7.1.1 Assumptions and Rationale
7.1.2 Total Incidence of Breast Cancer in the United States
7.1.3 Incidence of Breast Cancer Cases by Menopausal Status in the United States
7.1.4 Stage-Specific Incidence of Breast Cancer in Post Menopausal Women in the United States
7.1.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the United States
7.1.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in the United States
7.1.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in the United States
7.2 EU5 Countries
7.3 Germany
7.3.1 Assumptions and Rationale
5.3.2. Total Incidence of Breast Cancer in Germany
5.3.3. Incidence of Breast Cancer Cases by Menopausal Status in Germany
5.3.4. Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Germany
5.3.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Germany
5.3.6. Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in Germany
5.3.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in Germany
7.4 France
7.4.1 Assumptions and Rationale
7.4.2 Total Incidence of Breast Cancer in France
7.4.3 Incidence of Breast Cancer Cases by Menopausal Status in France
7.4.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in France
7.4.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in France
7.4.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in France
7.4.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in France
7.5 Italy
7.5.1 Assumptions and Rationale
7.5.2 Total Incidence of Breast Cancer in Italy
7.5.3 Incidence of Breast Cancer Cases by Menopausal Status in Italy
7.5.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Italy
7.5.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Italy
7.5.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in Italy
7.5.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in Italy
7.6 Spain
7.6.1 Assumptions and Rationale
7.6.2 Total Incidence of Breast Cancer in Spain
7.6.3 Incidence of Breast Cancer by Menopausal Status in Spain
7.6.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Spain
7.6.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Spain
7.6.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause Cases by Molecular Subtype in Spain
7.6.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause Cases by Molecular Subtype in Spain
7.7 The United Kingdom
7.7.1 Assumptions and Rationale
7.7.2 Total Incidence of Breast Cancer in the United Kingdom
7.7.3 Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom
7.7.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the United Kingdom (2017–2030)
7.7.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the United Kingdom
7.7.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in the United Kingdom
7.7.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in the United Kingdom
7.8 Japan
7.8.1 Assumptions and Rationale
7.8.2 Total Incidence of Breast Cancer in Japan
7.8.3 Incidence of Breast Cancer Cases by Menopausal Status in Japan
7.8.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Japan (2017–2030)
7.8.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the Japan
7.8.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in Japan
7.8.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in Japan

8 Treatment of Estrogen-Receptor (ER)-Positive Breast Cancer

8.1.1 Endocrine Therapy
8.1.2 Aromatase inhibitors (AIs)
8.1.3 Endocrine Therapy (ET) Options to Manage Resistance
8.1.4 Targeted CDK4/6 Inhibitors
8.1.5 mTOR Inhibitors
8.1.6 Akt Inhibitors
8.2 Treatment Algorithm of Estrogen Receptor (ER)-Positive Breast Cancer
8.3 Treatment Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer
8.3.1 American Society of Clinical Oncology (ASCO) Clinical Practice Guideline: Adjuvant Endocrine Therapy for Women with Hormone-receptor-positive Breast Cancer
8.3.2 Italian Association of Medical Oncology (AIOM): Adjuvant Endocrine Therapy in Premenopausal Patients with Hormone-receptor-positive Early Breast Cancer
8.3.3 The Japanese Breast Cancer Society: Clinical Practice Guideline for systemic treatment of breast cancer

9 Marketed Products

9.1 Ibrance (Palbociclib): Pfizer
9.1.1 Product Description
9.1.2 Regulatory Milestones
9.1.3 Other Developmental Activities
9.1.4 Current Pipeline Activity
9.1.5 Safety and efficacy
9.1.6 Product Profile
9.2 Piqray (Alpelisib; BYL719): Novartis
9.2.1 Product Description
9.2.2 Regulatory Milestones
9.2.3 Other Developmental Activities:
9.2.4 Clinical Development
9.2.5 Safety and Efficacy
9.2.6 Product Profile
9.3 Lynparza (olaparib): AstraZeneca Pharmaceuticals
9.3.1 Product Description
9.3.2 Regulatory Milestones
9.3.3 Other Developmental Activities
9.3.4 Clinical Development
9.3.5 Safety and efficacy
9.3.6 Product Profile
9.4 Verzenio (Abemaciclib): Eli Lilly
9.4.1 Product Description
9.4.2 Regulatory Milestones
9.4.3 Other Developmental Activities
9.4.4 Clinical Development
9.4.5 Safety and efficacy
9.4.6 Product Profile
9.5 Kisqali (Ribociclib; LEE011): Novartis Pharmaceuticals
9.5.1 Product Description
9.5.2 Regulatory Milestones
9.5.3 Other Developmental Activities
9.5.4 Clinical Development
9.5.5 Safety and efficacy
9.5.6 Product Profile
9.6 Afinitor (Everolimus): Novartis
9.6.1 Product Description
9.6.2 Regulatory Milestones
9.6.3 Other Developmental Activities
9.6.4 Clinical Development
9.6.5 Safety and efficacy
9.6.6 Product Profile
9.7 Faslodex (Fulvestrant) Injection: AstraZeneca
9.7.1 Product Description
9.7.2 Regulatory Milestones
9.7.3 Other Developmental Activities
9.7.4 Clinical Development
9.7.5 Safety and efficacy
9.7.6 Product Profile
9.8 Arimidex (Anastrozole): AstraZeneca
9.8.1 Product Description
9.8.2 Regulatory Milestones
9.8.3 Other Developmental Activities
9.8.4 Clinical Development
9.8.5 Safety and efficacy
9.8.6 Product Profile
9.9 Aromasin (Exemestane): Pharmacia and Upjohn Company
9.9.1 Product Description
9.9.2 Regulatory Milestones
9.9.3 Other Developmental Activities
9.9.4 Clinical Development
9.9.5 Safety and Efficacy
9.9.6 Product Profile
9.1 Femara (Letrozole): Novartis Pharmaceuticals
9.10.1 Product Description
9.10.2 Regulatory Milestones
9.10.3 Other Developmental Activities
9.10.4 Clinical Development
9.10.5 Safety and efficacy
9.10.6 Product Profile

10 Unmet Needs

11 Emerging Drugs

11.1 Key Cross Competition
11.2 SHR6390: Jiangsu HengRui Medicine Co.
11.2.1 Product Description
11.2.2 Clinical Development
11.2.3 Safety and Efficacy
11.2.4 Product Profile
11.3 Tesetaxel: Odonate Therapeutics
11.3.1 Product Description
11.3.2 Other Development Activities
11.3.3 Clinical Development
11.3.4 Safety and Efficacy
11.3.5 Product Profile
11.4 Elacestrant (RAD1901): Radius Pharmaceuticals
11.4.1 Product Description
11.4.2 Other Development Activities
11.4.3 Clinical Development
11.4.4 Safety and Efficacy
11.4.5 Product Profile
11.5 Sacituzumab Govitecan (IMMU-132): Immunomedics
11.5.1 Product Description
11.5.2 Other Development Activities
11.5.3 Clinical Development
11.5.4 Product Profile
11.6 Ipatasertib (RG7440): Roche
11.6.1 Product Description
9.1.1. Other Development Activities
11.6.2 Clinical Development
11.6.3 Product Profile
11.7 Venclexta: Roche
11.7.1 Product Description
11.7.2 Other Development Activities
11.7.3 Clinical Development
11.7.4 Safety and Efficacy
11.7.5 Product Profile
11.8 Entinostat: Syndax Pharmaceuticals
11.8.1 Product Description
11.8.2 Other Developmental Activities
11.8.3 Clinical Development
11.8.4 Safety and Efficacy
11.8.5 Product Profile
11.9 Pembrolizumab (MK-3475): Merck Sharp and Dohme
11.9.1 Product Description
11.9.2 Other development Activities
11.9.3 Clinical Development
11.9.4 Product Profile
11.1 Eribulin Mesylate: Merck Sharp & Dohme Corp.
11.10.1 Product Description
11.10.2 Other development Activities
11.10.3 Clinical Development
11.10.4 Product Profile
11.11 MM-121: Merrimack Pharmaceuticals
11.11.1 Product Description
11.11.2 Other Development Activities
11.11.3 Clinical Development
11.11.4 Safety and Efficacy
11.11.5 Product Profile
11.12 GSK525762 (Molibresib): GlaxoSmithKline
11.12.1 Product Description
11.12.2 Other Development Activities
11.12.3 Clinical Development
11.12.4 Safety and Efficacy
11.12.5 Product Profile
11.13 Sapanisertib (TAK-228): Takeda Pharmaceuticals
11.13.1 Product Description
11.13.2 Other Development Activities
11.13.3 Clinical Development
11.13.4 Safety and Efficacy
11.13.5 Product Profile
11.14 Radium-223 dichloride: Bayer
11.14.1 Product Description
11.14.2 Other Development Activities
11.14.3 Clinical Development
11.14.4 Product Profile
11.15 EGL-5385-C-1701(fulvestrant): Eagle Pharmaceuticals
11.15.1 Product Description
11.15.2 Other Development Activities
11.15.3 Clinical Development
11.15.4 Product Profile

12 HR+/HER2- Post Menopause Breast Cancer: The 7 Major Market Analysis

12.1 Key Findings
12.1.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM
12.1.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the 7MM
12.1.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the 7MM
12.1.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM
12.1.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM

13 The United States Market Analysis

13.1 The United States Market Outlook
13.2 United States Market Size
13.2.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States
13.2.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the United States
13.2.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the United States
13.2.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States
13.2.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States

14 EU-5 Market Analysis

14.1 EU-5 Market Outlook
14.2 Germany Market Size
14.2.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Germany
14.2.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Germany
14.2.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Germany
14.2.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany
14.2.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany
14.3 France Market Size
14.3.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France
14.3.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in France
14.3.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in France
14.3.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France
14.3.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France
14.4 Italy Market Size
14.4.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy
14.4.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Italy
14.4.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Italy
14.4.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy
14.4.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy
14.5 Spain Market Size
14.5.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain
14.5.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Spain
14.5.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Spain
14.5.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain
14.5.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain
14.6 The United Kingdom Market Size
14.6.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom
14.6.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the United Kingdom
14.6.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the United Kingdom
14.6.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom
14.6.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom

15 Japan Market Outlook

15.1 Japan Market Size
15.1.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan
15.1.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Japan
15.1.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Japan
15.1.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan
15.1.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan

16 Access and Reimbursement Overview of Breast Cancer

17 Case Reports

17.1 Case Study in Breast Cancer: Primary Treatment of HR-positive, HER2-negative Advanced Breast Cancer
17.2 Case Studies in the Management of Metastatic Breast Cancer with Eribulin

18 Market Drivers

19 Market Barriers

20 Appendix

20.1 Report Methodology

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight

List of Tables
Table 1: Total Incidence of Breast Cancer in the 7MM (2017–2030)
Table 2: Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2030)
Table 3: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
Table 4: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
Table 5: Total Incidence of Breast Cancer in the United States (2017–2030)
Table 6: Incidence of Breast Cancer by Menopausal Status in the United States (2017–2030)
Table 7: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the United States (2017–2030)
Table 8: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the United States (2017–2030)
Table 9: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in the United States (2017–2030)
Table 10: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the United States (2017–2030)
Table 11: Incidence of Breast Cancer in Germany (2017–2030)
Table 12: Incidence of Breast Cancer by Menopausal Status in Germany (2017–2030)
Table 13: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Germany (2017–2030)
Table 14: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Germany (2017–2030)
Table 15: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype Cases in Germany (2017–2030)
Table 16: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype Cases in Germany (2017–2030)
Table 17: Total Incidence of Breast Cancer in France (2017–2030)
Table 18: Incidence of Breast Cancer by Menopausal Status in France (2017–2030)
Table 19: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in France (2017–2030)
Table 20: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in France (2017–2030)
Table 21: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in France (2017–2030)
Table 22: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in France (2017–2030)
Table 23: Total Incidence of Breast Cancer in Italy (2017–2030)
Table 24: Incidence of Breast Cancer by Menopausal Status in Italy (2017–2030)
Table 25: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Italy (2017–2030)
Table 26: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Italy (2017–2030)
Table 27: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Italy (2017–2030)
Table 28: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Italy (2017–2030)
Table 29: Total Incidence of Breast Cancer in Spain (2017–2030)
Table 30: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2030)
Table 31: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Spain (2017–2030)
Table 32: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Spain (2017–2030)
Table 33: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Spain (2017–2030)
Table 34: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Spain (2017–2030)
Table 35: Total Incidence of Breast Cancer in the United Kingdom (2017–2030)
Table 36: Incidence of Breast Cancer by Menopausal Status in the United Kingdom (2017–2030)
Table 37: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the UK (2017–2030)
Table 38: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the UK (2017–2030)
Table 39: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in the United Kingdom (2017–2030)
Table 40: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the United Kingdom (2017–2030)
Table 41: Total Incidence of Breast Cancer in Japan (2017–2030)
Table 42: Incidence of Breast Cancer by Menopausal Status in Japan (2017–2030)
Table 43: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Japan (2017–2030)
Table 44: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the Japan (2017–2030)
Table 45: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Japan (2017–2030)
Table 46: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Japan (2017–2030)
Table 47: Classification of Aromatase Inhibitors
Table 48: Summary of All Recommendations (Original Recommendations and Focused Update Recommendations)
Table 49: Ibrance, Clinical Trial Description, 2020
Table 50: Piqray, Clinical Trial Description, 2019
Table 51: Olaparib, Clinical Trial Description, 2020
Table 52: Verzenio, Clinical Trial Description, 2020
Table 53: KISQALI, Clinical Trial Description, 2020
Table 54: Faslodex, Clinical Trial Description, 2020
Table 55: Arimidex, Clinical Trial Description, 2020
Table 56: SHR6390, Clinical Trial Description, 2020
Table 57:, Tesetaxel, Clinical Trial Description, 2020
Table 58: Elacestrant (RAD1901), Clinical Trial Description, 2020
Table 59: Sacituzumab govitecan, Clinical Trial Description, 2020
Table 60: Ipatasertib, Clinical Trial Description, 2020
Table 61: Venetoclax, Clinical Trial Description, 2020
Table 62: Entinostat, Clinical Trial Description, 2020
Table 63: Pembrolizumab, Clinical Trial Description, 2020
Table 64: Eribulin Mesylate, Clinical Trial Description, 2020
Table 65: Seribantumab, Clinical Trial Description, 2020
Table 66: GSK525762 (Molibresib), Clinical Trial Description, 2020
Table 67: TAK-228 (INK128, MLN0128), Clinical Trial Description, 2020
Table 68: Radium 223 dichloride (BAY88-8223), Clinical Trial Description, 2020
Table 69: EGL-5385-C-1701(fulvestrant): Clinical Trial Description, 2020
Table 70: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM, USD Millions (2017–2030)
Table 71: 7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)
Table 72:7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)
Table 73: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2030)
Table 74: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2030)
Table 75: Novel drugs recently approved for treating HR-positive/ HER2-negative Breast Cancer
Table 76: Expected Launch Date of Emerging Drugs in the United States
Table 77: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States, USD Millions (2017–2030)
Table 78: United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)
Table 79:United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)
Table 80: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2030)
Table 81: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2030)
Table 82: Expected Launch Date of Emerging Drugs in EU-5 Countries
Table 77: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Germany, USD Millions (2017–2030)
Table 78: Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)
Table 79: Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)
Table 80: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2030)
Table 81: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2030)
Table 82: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France, USD Millions (2017–2030)
Table 83: France Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)
Table 84: France Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)
Table 85: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2030)
Table 86: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2030)
Table 87: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy, USD Millions (2017–2030)
Table 88: Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)
Table 89: Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)
Table 90: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2030)
Table 91: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2030)
Table 92: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain, USD Millions (2017–2030)
Table 93: Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)
Table 94: Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)
Table 95: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2030)
Table 96: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2030)
Table 97: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom, USD Millions (2017–2030)
Table 98: United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)
Table 99: United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)
Table 100: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: United Kingdom, in USD Million (2017–2030)
Table 101: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: United Kingdom, in USD Million (2017–2030)
Table 102: Expected Launch Date of Emerging Drugs in Japan
Table 103: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan, USD Millions (2017–2030)
Table 104: Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)
Table 105: Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)
Table 106: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2030)
Table 107: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2030)

List of Figures
Figure 1: SWOT analysis for Breast Cancer
Figure 2: Types of Receptor on Breast Cancer
Figure 3: Molecular Subtypes of Breast Cancer
Figure 4: Molecular Subtypes of Breast Cancer
Figure 5: Working of Estrogen Receptor
Figure 6: Schematic Structure of the Estrogen Receptor (ER) Depicting Six Domains.
Figure 7: ER pathway and mechanisms of resistance. Estrogen-bound estrogen receptor (ER), in association with a variety of coactivators and co-repressors, exerts its classical genomic action as a transcription factor through the estrogen response element (ERE) of target genes.
Figure 8: Metabolism of Estrogen Receptor-Positive Breast Cancer
Figure 9: Symptoms of HR-Positive Breast Cancer.
Figure 10: Lifestyle-related Breast Cancer Risk Factors
Figure 11: Diagnosis of ER-Positive Breast Cancer
Figure 12: Assays for Measuring Estrogen and Progesterone Receptor
Figure 13: Essential Elements Required for Accurate Testing of ERa And PGr Status In Breast Cancer by Immunohistochemistry.
Figure 14: Total Incidence of Breast Cancer in the 7MM (2017–2030)
Figure 15:Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2030)
Figure 16: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
Figure 17: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
Figure 18: Total Incidence of Breast Cancer in the United States (2017–2030)
Figure 19: Incidence of Breast Cancer Cases by Menopausal Status in the United States (2017–2030)
Figure 20: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the United States (2017–2030)
Figure 21: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the United States (2017–2030)
Figure 22: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in the United States (2017–2030)
Figure 23: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the United States (2017–2030)
Figure 24: Total Incidence of Breast Cancer in Germany (2017–2030)
Figure 25: Incidence of Breast Cancer Cases by Menopausal Status in Germany (2017–2030)
Figure 26: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Germany (2017–2030)
Figure 27: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Germany (2017–2030)
Figure 28: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype Cases in Germany (2017–2030)
Figure 29: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype Cases in Germany (2017–2030)
Figure 30: Total Incidence of Breast Cancer in France (2017–2030)
Figure 31: Incidence of Breast Cancer Cases by Menopausal Status in France (2017–2030)
Figure 32: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in France (2017–2030)
Figure 33: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in France (2017–2030)
Figure 34: Diagnosed Incidence of early Stage Breast Cancer in Postmenopause by Molecular Subtype in France (2017–2030)
Figure 35: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in France (2017–2030)
Figure 36: Total Incidence of Breast Cancer in Italy (2017–2030)
Figure 37: Incidence of Breast Cancer Cases by Menopausal Status in Italy (2017–2030)
Figure 38: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Italy (2017–2030)
Figure 39: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Italy (2017–2030)
Figure 40: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Italy (2017–2030)
Figure 41: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Italy (2017–2030)
Figure 42: Total Incidence of Breast Cancer in Spain (2017–2030)
Figure 43: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2030)
Figure 44: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Spain (2017–2030)
Figure 45: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Spain (2017–2030)
Figure 46: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause Cases by Molecular Subtype in Spain (2017–2030)
Figure 47: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause Cases by Molecular Subtype in Spain (2017–2030)
Figure 48: Total Incidence of Breast Cancer in the United Kingdom (2017–2030)
Figure 49: Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom (2017–2030)